AFUGEM: Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Study Details
Study Description
Brief Summary
To evaluate the combination of ABI-007 with gemcitabine or with LV5FU2.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Gemcitabine alone or the triplet combination of 5FU, irinotecan and oxaliplatin (FOLFIRINOX)are the reference 1st line treatment for metastatic pancreatic cancer.
The aim of the AFUGEM study is to evaluate the efficacy of weekly ABI-007 in combination with weekly gemcitabine or with fortnightly simplified LV5FU2 regimen in terms of progression-free survival in patients with previously untreated metastatic pancreatic cancer.
ABI-007 has been approved for commercialization in 38 countries, including the US, Canada, the EU, Australia, China, India and Korea for the treatment of women with metastatic breast cancer. ABI-007 alone and in combination is being evaluated in a number of cancers, including metastatic melanoma, non-small cell lung cancer, pancreatic cancer, and other solid tumors. Conditions which are responsive to paclitaxel such as non-hematological solid tumor malignancies are good clinical candidates for treatment with ABI-007.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: ARM 1 ABI-007 + Gemcitabine ABI-007 : 125mg/m² IV / 30min (day 1, day 8, day 15) Gemcitabine : 1000mg/m² IV /30 min (day 1, day 8, day 15) One cycle every four weeks treatment until progression or limiting toxicity |
Drug: ABI-007
ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
Other Names:
Drug: Gemcitabine
1000 mg/m² IV /30min (day 1, day 8, day 15)
Other Names:
|
| Experimental: Arm 2 ABI-007 + simplified LV5FU2 ABI-007 : 125mg/m² IV /30 min (day 1, day 15) folinic acid : 400mg/m² IV /2h (day 1, day 15) Bolus 5-FU : 400mg/m² IV /15min 5-FU infusion : 2400mg/m² IV / 46h (day 1-2, day 15-16) One cycle every four weeks Treatment until progression or limiting toxicity |
Drug: ABI-007
ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
Other Names:
Drug: simplified LV5FU2
Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
|
Outcome Measures
Primary Outcome Measures
- Progression-free survival (PFS) [time interval from randomization to the date of first documented disease progression or death from any cause, whichever occurs first.Assessed at 4 months.]
To evaluate the efficacy of weekly ABI-007 in combination with weekly gemcitabine or with fortnightly simplified LV5FU2 regimen in terms of progression-free survival in patients with previously untreated metastatic pancreatic cancer
Secondary Outcome Measures
- Tumor Response Rate [Assessed every 2 months during treatment period (- Estimated treatment duration per patient : 6 months).]
Assessed using RECIST version 1.1
- Duration of disease control (DDC) [Assessed up to 30 months after the beginning of the study]
- Overall Survival [time interval from inclusion to the date of death from any cause. Assessed up to 30 months after the beginning of the study.]
- Quality of life [Assessed from study entry to 1 month after last study drug administration and up to 30 months after the beginning of the study.]
EORTC QLQ C-30
- Number of Adverse Events [Assessed from study entry to 1 month after last study drug administration, assessed up to 30 months after the beginning of the study]
To evaluate the safety profile of ABI-007 in combination with sLV5FU2 (NCI CTCAE v4.0)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed and dated informed consent, and willing and able to comply with protocol requirements,
-
Histologically or cytologically proven adenocarcinoma of the pancreas,
-
Metastatic disease confirmed (stage IV),
-
No prior therapy for metastatic disease (in case of previous adjuvant therapy, interval from end of chemotherapy and relapse must be >12 months),
-
At least one measurable or evaluable lesion as assessed by CT-scan or MRI (Magnetic Resonance Imaging) according to RECIST v1.1 guidelines,
-
Age ≥18 years,
-
ECOG Performance status (PS) 0-2,
-
Hematological status: neutrophils (ANC) >1.5x109/L; platelets >100x109/L; haemoglobin ≥9g/dL,
-
Adequate renal function: serum creatinine level <150µM,
-
Adequate liver function: AST (SGOT) and ALT (SGPT) ≤2.5xULN (≤5xULN in case of liver metastases)
-
Total bilirubin ≤1.5 x ULN, albumin ≥25g/L
-
Baseline evaluations performed before randomization: clinical and blood evaluations no more than 2 weeks (14 days) prior to randomization, tumor assessment (CT-scan or MRI, evaluation of non-measurable lesions) no more than 3 weeks (21 days) prior to randomization,
-
Female patients must be surgically sterile, or be postmenopausal, or must commit to using reliable and appropriate methods of contraception during the study and during at least six months after the end of study treatment (when applicable). All female patients with reproductive potential must have a negative pregnancy test (β HCG) within 72 hours prior to starting ABI-007 treatment. Breastfeeding is not allowed. Male patients must agree to use effective contraception in addition to having their partner use a contraceptive method as well during the trial and during at least six months after the end of the study treatment,
-
Registration in a national health care system (CMU included for France).
Exclusion Criteria:
-
History or evidence upon physical examination of CNS metastasis unless adequately treated (e.g. non irradiated CNS metastasis, seizure not controlled with standard medical therapy)
-
Local or locally advanced disease (stage I to III),
-
Patient uses warfarin,
-
Uncontrolled hypercalcemia,
-
Pre-existing permanent neuropathy (NCI grade ≥2),
-
Known dihydropyrimidine dehydrogenase (DPD) deficiency,
-
Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy),
-
Treatment with any other investigational medicinal product within 28 days prior to study entry,
-
Other serious and uncontrolled non-malignant disease (eg. active infection requiring systemic therapy, coronary stenting or myocardial infarction or stroke in the past 6 months),
-
Known or historical active infection with HIV, or known active infection untreated with hepatitis B or hepatitis C.
-
History or active interstitial lung disease (ILD),
-
Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years,
-
Patients with known allergy to any excipient of study drugs,
-
Concomitant administration of live, attenuated virus vaccine such as yellow fever vaccine and concomitant administration of prophylactic phenytoin
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Institut de cancérologie de l'Ouest - Paul Papin | Angers | France | ||
| 2 | Institut Sainte Catherine | Avignon | France | ||
| 3 | Hôpital Avicenne | Bobigny | France | ||
| 4 | Hôpital Beaujon | Clichy | France | ||
| 5 | Hôpital Henri Mondor | Créteil | France | ||
| 6 | Hôpital Privé Jean Mermoz | Lyon | France | ||
| 7 | CHU la Timone | Marseille | France | ||
| 8 | Centre Hospitalier Layné | Mont de Marsan | France | ||
| 9 | Hôpital Européen Georges Pompidou | Paris | France | ||
| 10 | Hôpital Pitié-Salpêtrière | Paris | France | ||
| 11 | Hôpital Saint Antoine | Paris | France | ||
| 12 | Institut Mutualiste Montsouris | Paris | France | ||
| 13 | CHU de Reims Hôpital Robert Debré | Reims | France | ||
| 14 | Institut de Cancérologie de l'Ouest - Réné Gauducheau | Saint Herblain | France | 44805 | |
| 15 | Hôpital Trousseau - CHRU Tours | Tours | France |
Sponsors and Collaborators
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Celgene Corporation
Investigators
- Principal Investigator: Jean-Baptiste Bachet, MD, Hôpital La Pitié-Salpêtrière
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AFUGEM D12-2
- 2013-001463-23